CAMBRIDGE--The American Kidney Fund and Genzyme Corp. have teamed up to launch a program that will provide Renagel to Medicare patients who can't afford co-payments for the phosphorus drug.
"Genzyme is delighted to expand out partnership with the American Kidney Fund to ensure that Renagel is accessible to all patients who need it," Genzyme Renal President John Butler said in a statement. "High Medicare co-payments can pose a serious obstacle for many patients, and we are committed to helping Medicare patients access Renagel."
The joint Medicare Part D Assistance Program is designed to help patients facing higher payments in and out of what is known as the "donut hole," which is when beneficiaries will not recieve assistance with drug payments. When drug costs reach $2,250, patients will pay an additional $2,850 before Medicare Part D continues coverage.
To be eligible, patients must be enrolled in a Medicare Part D prescription drug plan, have no alternative insurance, meet certain income criteria, and have spent a certain percentage of their income on prescription drugs.
Qualified patients will receive Renagel at no cost through the end of 2006. Call (800) 847-0069 for more information.
Email this article
Add a comment
Printer version
Order reprints
RSS Feed
Bookmark article